$ABBV 0.45 Noisy

Notable posts

• @WOLF_Financial neutral 704 eng

  HERE ARE THE WORLD'S 50 MOST VALUABLE COMPANIES AS OF JUNE 2026 TECHNOLOGY (22 of the top 50): NVIDIA $NVDA: $4.8T Apple $AAPL: $4.3T Alphabet $GOOGL: $4.2T Microsoft $MSFT: $2.8T SpaceX $SPCX: $2.1T TSMC $TSM: $2.3T Broadcom $AVGO: $1.8T Samsung: $1.5T Meta $META: $1.4T SK Hynix: $1.2T Micron $MU: $1.2T AMD $AMD: $848B Intel $INTC: $665B ASML $ASML: $685B Arm $ARM: $391B Cisco $CSCO: $478B Oracle $ORCL: $476B Applied Materials $AMAT: $465B Lam Research $LRCX: $464B KLA $KLAC: $319B Tencent: $485B Kioxia: $313B CONSUMER DISCRETIONARY: Amazon $AMZN: $2.5T Tesla $TSLA: $1.4T Home Depot $HD: $324B ENERGY: Saudi Aramco: $1.7T ExxonMobil $XOM: $579B Chevron $CVX: $350B FINANCIALS: Berkshire Hathaway $BRK: $1.1T JPMorgan Chase $JPM: $895B Visa $V: $625B Mastercard $MA: $431B Bank of America $BAC: $411B Morgan Stanley $MS: $357B Goldman Sachs $GS: $323B China Construction Bank: $382B Agricultural Bank of China: $326B ICBC: $308B HSBC $HSBC: $328B CONSUMER STAPLES: Walmart $WMT: $950B Costco $COST: $425B Procter & Gamble $PG: $351B Coca-Cola $KO: $346B HEALTH CARE: Lilly $LLY: $987B Johnson & Johnson $JNJ: $576B AbbVie $ABBV: $415B UnitedHealth $UNH: $372B INDUSTRIALS: Caterpillar $CAT: $453B P&G $PG: $351B (also listed under consumer staples) GE $GE: $372B (Photo Credit: VisualCapitalist)

  view on X →
• @StockSavvyShay neutral 664 eng

  NEXT WEEKS EARNINGS ARE MASSIVE • Monday | $APLD, $NVTS, $CDNS, $AMKR • Tuesday | $BE, $KLAC, $PYPL, $V, $TER, $ENPH • Wednesday | $MSFT, $META, $HOOD, $ARM, $QCOM, $SOFI, $VRT, $LMND, $LRCX, $VKTX, $FTNT, $CVNA • Thursday | $AAPL, $AMZN, $COIN, $RBLX, $RDDT, $TEM, $RIVN, $FSLR, $MA, $PGY, $MSTR, $AXTI, $NXT • FRIDAY | $CVX, $XOM, $ABBV, $CCJ, $MRNA

  view on X →
• @wallstengine neutral 55 eng

  ABBVIE $ABBV Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $16.99B (Est. $16.77B) 🟢; +10.2% YoY 🔹 Adj. EPS: $3.65 (Est. $3.60) 🟢; +22.9% YoY 🔹 Immunology Portfolio Revenue: $8.79B; +15.1% YoY Cuts FY26 Guide: 🔹 Adj. EPS: $13.87-$14.07 (Est. $14.08) 🟡; from $13.91-$14.11 Segment Net Revenue: 🔹 Immunology: $8.79B; +15.1% YoY 🔹 Neuroscience: $3.23B; +20.3% YoY 🔹 Oncology: $1.65B; -1.5% YoY 🔹 Aesthetics: $1.28B; +0.3% YoY Other Q2 Metrics: 🔹 Skyrizi Revenue: $5.51B; +24.4% YoY 🔹 Rinvoq Revenue: $2.53B; +24.5% YoY 🔹 Humira Revenue: $756M; -35.9% YoY M&A: 🔹 Apogee Therapeutics: Definitive agreement to acquire; expected to close in Q3 2026 Comments: 🔸 “We also announced the proposed acquisition of Apogee Therapeutics, which strengthens our ability to deliver innovative medicines to patients, bolsters our immunology leadership and creates significant shareholder value.” 🔸 “Based on our substantial momentum, AbbVie's long-term outlook remains very strong.”

  view on X →
• @wallstengine neutral 52 eng

  Today's Key Events (All EST) — 07/31/2026 06:00: $ARES 06:00: Patria $PAX 06:00: Proto Labs $PRLB 06:00: Perimeter Solutions $PRM 06:05: AngloGold Ashanti $AU 06:10: Carter’s $CRI 06:15: Chevron $CVX 06:30: Exxon Mobil $XOM 06:30: Eaton $ETN 06:30: Lear $LEA 06:30: LyondellBasell $LYB 06:30: nVent Electric $NVT 06:30: Newell Brands $NWL 06:35: Cameco $CCJ 06:45: Brookfield Business $BBUC 06:55: AutoNation $AN 06:55: Church & Dwight $CHD 06:55: Colgate-Palmolive $CL 06:55: Brookfield Renewable $BEP 07:00: Balchem $BCPC 07:00: TransAlta $TAC 07:00: T. Rowe Price $TROW 07:00: WisdomTree $WT 07:30: Dominion Energy $D 07:30: Ballard Power Systems $BLDP 07:30: Federal Realty $FRT 07:30: Cboe Global Markets $CBOE 07:30: Gates Industrial $GTES 07:45: AbbVie $ABBV 07:55: Moog $MOG.A 08:00: Nano-X Imaging $NNOX 08:00: RBC Bearings $RBC 08:20: Franklin Resources $BEN 08:30: Arbor Realty Trust $ABR 08:30: iRadimed $IRMD

  view on X →
• @wallstengine neutral 37 eng

  $ABBV is closing in on a nearly $11B cash deal to buy Apogee Therapeutics, per FT. The discussed deal would value $APGE at $10.9B, roughly a 60% premium to Thursday’s close, and could be announced as soon as Today. Apogee’s lead drug, zumilokibart, is being developed as a longer-acting alternative to Dupixent, with dosing studied every 3 to 6 months vs. Dupixent’s every 2 weeks. Apogee plans to start a Phase 3 trial in atopic dermatitis later this year.

  view on X →
• @StockOptionCole neutral 32 eng

  Massive week ahead Wednesday • 2:00 PM – FOMC Interest Rate Decision • 2:30 PM – Fed Chair Press Conference (Kevin Warsh) Mon: $APLD $AMKR $CLS $RMBS Tue: $V $BE $KLAC $GLW $STX $NXPI Wed: $MSFT $META $VRT $ARM $QCOM $LRCX Thu: $AAPL $AMZN $COIN $MSTR $RDDT $RBLX Fri: $CVX $XOM $CCJ $ETN $ABBV AI CapEx • Cloud Growth • GPU Demand • Memory • Data Centers • Infrastructure Watch for read-throughs into $NVDA $MU $MRVL $AVGO $AMD $NBIS $DELL $TSM $QQQ $SMH

  view on X →
• @wallstengine neutral 26 eng

  $ABBV said the European Commission approved Maviret for acute hepatitis C in adults and children ages 3+. Maviret was already approved in the EU for chronic HCV, and AbbVie says it is now the only EU-approved treatment for both acute and chronic HCV in that age group. Phase 3 data showed 96.2% SVR12 in the intent-to-treat population, with no on-treatment virologic failures or post-treatment relapses.

  view on X →
• @faststocknewss neutral 13 eng

  ABBVIE $ABBV REPORTS POSITIVE PHASE 3 EPCORITAMAB DATA IN LYMPHOMA AbbVie reported positive results from a Phase 3 trial of epcoritamab plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), per the company. Epcoritamab, marketed as Epkinly and developed with Genmab $GMAB, is a bispecific antibody already approved as a monotherapy for R/R DLBCL. DLBCL is the most common form of non-Hodgkin lymphoma.

  view on X →